Italian authorities have seized five shipments from South Korea containing botulinum toxin vials and lidocaine syringes at Fiumicino Airport, uncovering a nationwide illegal trade in aesthetic medicine products. The operation, named "DORIAN GRAY," highlights risks for overseas buyers sourcing injectables without proper import documentation or cold chain compliance, potentially endangering patient safety and market integrity.
Operation details
The seizures were conducted by the Fiumicino Group of the Financial Police and the Customs and Monopolies Agency Lazio 2 at the airport's cargo sorting area. Investigators intercepted 139 shipments containing illegally imported medicines, including 1,409 vials of liquid solution equivalent to about 44,000 doses of botulinum toxin, and approximately 6,000 related medical products. The shipments were destined for various Italian regions, particularly in the south.
Regulatory violations
The products were shipped without required import authorization and without maintaining the cold chain essential for preservation, violating Italian Legislative Decree 219/2006, which implements EU Directive 2001/83/EC. The Ministry of Health's USMAF-SASN offices confirmed the shipments were non-compliant and inadmissible for entry. Products were falsely declared as "cosmetic samples," "lotions," "moisturizing creams," or "sewing machine needles" to evade health controls.
Legal consequences
A total of 113 individuals have been reported for violations under Articles 55 and 147 of Legislative Decree 219/2006. Authorities conducted 44 personal and premises searches across multiple Italian regions. Five doctors were reported to their professional register, and tax audits were initiated against three illegal aesthetic centers unknown to tax authorities. The investigation also targets tax evasion and the underground economy linked to this illicit trade.
What buyers should watch
For overseas importers and distributors of aesthetic injectables, this case underscores the critical importance of verifying supply chain compliance. Products lacking proper import documentation, cold chain records, and regulatory approvals pose serious safety risks and legal liabilities. Buyers should ensure suppliers provide full traceability, including certificates of analysis, batch numbers, and temperature logs. Engaging with unauthorized sources may lead to product seizures, legal penalties, and reputational damage.
Sourcing context
South Korea is a major global hub for aesthetic injectables, including botulinum toxin products. However, this seizure highlights that not all products leaving the country meet international regulatory standards. Legitimate buyers should source only from manufacturers with established regulatory approvals in target markets, such as CE marking for Europe or FDA clearance for the United States. Due diligence on export documentation and cold chain logistics is essential to avoid counterfeit or diverted goods.
Source: Read the original report | Published: June 16, 2026